

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 8-K

CHINA PHARMA HOLDINGS, INC.

Form 8-K

September 21, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

FORM 8-K  
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): September 21, 2006

China Pharma Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-29523

73-1564807

(State of Incorporation)

(Commission File No.)

(IRS Employer ID No.)

2nd Floor, No. 17, Jinpan Road  
Haikou, Hainan Province, China  
(Address of Principal Executive Offices)

86-898-66811730

Registrant's Telephone Number, Including Area Code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

China Pharma Holdings, Inc. issued a press release on September 20, 2006. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Current Report included in this Item 2.02, including the exhibit included herewith, is furnished pursuant to Item 2.02 and shall not be

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 8-K

deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section.

Item 9.01. Financial Statements and Exhibits

Exhibits

99.1 Press release issued by the Company dated September 20, 2006.

---

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

China Pharma Holdings, Inc.

Date: September 21, 2006

/s/ Zhilin Li

---

Zhilin Li  
President and CEO